Healthcare writer

Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and Competitive analysis by DelveInsight| Companies – Selecta Biosciences, Arthrosi Therapeutics, AstraZeneca, Fuji Yakuhin

Gout is a common form of inflammatory arthritis. It’s due to a crystal called uric acid. Gout causes pain and swelling in one or more joints. It typically affects the big toe. But it’s also found in other joints, including the knee, ankle, foot, hand, wrist and elbow. It is more common in men than in women. Gout usually develops in middle age.

DelveInsight’s “Gout Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Gout, historical and forecasted epidemiology as well as the Gout market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To know more about the Gout Market Report, click here: Gout Market Assessment

View Report: https://www.delveinsight.com/report-store/gout-market

Some facts of Gout Market are:

In a study based on US National Health and Nutrition Examination Survey [NHANES] (n.d.), conducted in 2007–2008, 3.9% of the US population reported physician-diagnosed prevalent gout. The male to female ratio was 3:1.
Roddy et al. (2020) quoted that prevalence of gout vary widely according to the population studied and methods employed but range from a prevalence of <1% to 6.8%.
In the UK, based on the Clinical Practice Research Data link (CPRD) (2012), the prevalence of gout was 2.49% (95% CI, 2.48−2.51%) in 2012.
The prevalence of Gout is higher in men than in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.
According to the study conducted by Bonnemaire et al. (2008), the prevalence of gout in Germany was reported to be 1.4% in the general population in 2000–2005, which was the same prevalence as in the UK in that period, determined using the same case definition and data source. In comparison, France and Italy have a lower prevalence of gout.
SEL-212, AR882 and other emerging therapies are giving positive topline results, in their clinical trials. These emerging therapies are in mid phase of its clinical trials and are awaiting a launch which will make the pipeline for Gout robust.

To get detailed analysis of the Gout Market and Epidemiology facts, click here: Gout Market Analysis

View Report: https://www.delveinsight.com/report-store/gout-market

Scope of Gout Market Report:

The report covers the descriptive overview of Gout, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Gout epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Gout are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Gout market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gout market

Get the complete scope of the Gout Market: Gout Market Report

View Report: https://www.delveinsight.com/report-store/gout-market

Some of the Gout Companies in the market

Selecta Biosciences
Arthrosi Therapeutics
AstraZeneca
Fuji Yakuhin
And Others

Get access to free sample report, here: Gout Market Companies

View Report: https://www.delveinsight.com/report-store/gout-market

Gout Pipeline Therapies are:

SEL-212
AR882
Dotinurad (URECE)
ZURAMPIC (lesinurad)
And Others

To know more in detail about the Gout Companies and Pipeline Therapies, click here: Gout Pipeline Therapies and Drugs https://www.delveinsight.com/report-store/gout-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:

1. Key Insights

2. Executive Summary of Gout

3. Competitive Intelligence Analysis for Gout

4. Gout: Market Overview at a Glance

5. Gout: Disease Background and Overview

6. Patient Journey

7. Gout Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Gout Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Gout: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Gout

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

View Report: https://www.delveinsight.com/report-store/gout-market

Latest Report:

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

DelveInsight Estimates, Global endoscopes market is expected to grow at a CAGR of 6.05% during the forecast period from 2022 to 2027 to reach USD 18.32 billion by 2027 | Companies- Boston Scientific Corporation, CONMED Corporation, OLYMPUS CORPORATION, Stryker, Medtronic and Others

DelveInsight’s Endoscopes Market Insights and Forecast report provides the current and forecasted Endoscopes Market forecasts for next five years, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Endoscopes Market.

Endoscopes Overview:

Endoscopy is a medical procedure that is used to observe the inside of the body without performing major surgery. An endoscope is a long flexible tube with a lens at one end and a video camera at the other. The end with the lens is inserted into the patient. It is usually inserted through one of the body’s natural openings, such as the mouth, urethra, or anus.

To know more about the Endoscopes market Report, click here: https://www.delveinsight.com/report-store/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Endoscopes Market Report:

Global endoscopes market was valued at USD 12.95 billion in 2021, growing at a CAGR of 6.05% during the forecast period from 2022 to 2027 to reach USD 18.32 billion by 2027.
The increase in demand for endoscopes is primarily attributed to the increasing prevalence of chronic disease which require the use of endoscopes for diagnosis, such as some gastrointestinal diseases like irritable bowel syndrome (IBD), gastroesophageal reflux disease (GERD), peptic ulcer disease, and crohn’s disease, increase in number of geriatric population who are more prone to chronic ailments, increasing awareness and demand of minimally invasive surgeries and no blood loss surgery, and rise in technological advancements in endoscopes like image magnification, high-definition optical systems and digital imaging are anticipated to bolster the market, thereby contributing to the growth of the endoscopes market during the forecast period from 2022-2027.
According to Centers for Disease Control and Prevention (CDC) 2021, estimated that the number of adults with diagnosed gastrointestinal ulcers was 14.8 million in 2020.
According to WHO, in 2019, the number of people aged 60 years and older was 1 billion.

Get detailed analysis of the endoscopes market and facts, here: https://www.delveinsight.com/report-store/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the Endoscope Companies:

Boston Scientific Corporation
CONMED Corporation
OLYMPUS CORPORATION
PENTAX Medical
FUJIFILM Holdings America Corporation
Stryker
Karl Storz GmbH & Co.
Richard Wolf GmbH.
Medtronic
Machida Endoscope Co., Ltd
Pro Scope Systems
Laborie.
AED.MD
EMED
Happersberger otofront GmbH
Optomic.
EMOS Technology GmbH
Delmont imaging
Luxamed – Medical technology
Hangzhou Kangji Medical Instrument Co.,Ltd.
Daichuan medical
And Others

To get complete analysis of the Endoscope companies working in the market, click here: https://www.delveinsight.com/report-store/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Endoscopes Market Drivers:

The increase in demand for endoscopes is primarily attributed to the increasing prevalence of chronic disease which require the use of endoscopes for diagnosis, such as some gastrointestinal diseases like irritable bowel syndrome (IBD), gastroesophageal reflux disease (GERD), peptic ulcer disease, and crohn’s disease
Increase in number of geriatric population who are more prone to chronic ailments, increasing awareness and demand of minimally invasive surgeries and no blood loss surgery.
Rise in technological advancements in endoscopes like image magnification, high-definition optical systems and digital imaging are anticipated to bolster the market, thereby contributing to the growth of the endoscopes market during the forecast period from 2022-2027.

Request for Free sample Report: https://www.delveinsight.com/sample-request/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Endoscopes Report:

Study Period: 2019-2027

Base Year: 2021

Forecast Period: 2022-2027

Key Companies: Boston Scientific Corporation, CONMED Corporation, OLYMPUS CORPORATION, PENTAX Medical, FUJIFILM Holdings America Corporation, Stryker., Karl Storz GmbH & Co., KG, Richard Wolf GmbH., Medtronic, Machida Endoscope Co., Ltd, Pro Scope Systems, Laborie., AED.MD, EMED, Happersberger otofront GmbH, Optomic., EMOS Technology GmbH, Delmont imaging, Luxamed – Medical technology, Hangzhou Kangji Medical Instrument Co.,Ltd., Daichuan medical, and Others

Endoscopes Market Segmentation By Product Type: Coventional [Bronchoscopes, Duedonescopes, Colonscopes, Cystoscopes, Rhinoscopes, And Others] And Non-Conventional [Capsule Endoscopes And Robort-Assisted Endoscopes]

Endoscopes Market Segmentation By Flexibility Type: Flexible And Rigid

Endoscopes Market Segmentation By Disposability Type: Disposable And Reusable

Endoscopes Market Segmentation By Application Type: Gastrointestinal, Ent, Oncology, Respiratory, Gynacology, Urology And Others

Endoscopes Market Segmentation By End User: Hospitals And Clinics, Ambulatory Surgical Centers And Other

Endoscopes Market Segmentation By Geography: Global

Get free access to the sample report: https://www.delveinsight.com/sample-request/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents

1	Endoscopes Market Report Introduction
2	Endoscopes Market Executive summary
3	Regulatory and Patent Analysis
4	Endoscopes Market Key factors analysis
5	Endoscopes Porter’s Five Forces Analysis
6	COVID-19 Impact Analysis on Endoscopes Market
7	Endoscopes Market Layout
8	Endoscopes Global Company Share Analysis – Key 3-5 Companies
9	Endoscopes Companies and Product Profiles
10	Project Approach
11	KOL Views
12	DelveInsight Capabilities
13	Disclaimer
14	About DelveInsight

Get free access to the report and detailed TOC: https://www.delveinsight.com/report-store/endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Latest Report:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Global Menopause Market is anticipated to grow at a CAGR of 7.10% by 2027 | DelveInsight Estimates

DelveInsight’sMenopause Market Insights and Forecast report provides the current and forecast of Menopause, upcoming innovations, individual market shares of the products, challenges, drivers, and barriers, market trends, and key competitors in the Menopause Market scenario.

Some facts of the Menopause Market Report:

Global menopause market was valued at USD 15.53 billion in 2021, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 23.44 billion by 2027.
The demand for products that help in management of menopause symptoms is witnessing a surge majorly due to the rising female aging population wherein age plays a prominent role in regulating menstrual cycle and the growing awareness regarding menopause among people. Thereby boosting the growth of the menopause market during the forecast period from 2022-2027.
As per the figures quoted by the World Health Organization (WHO) in their Decade of Healthy Ageing (2020–2030) Report, the people in the age group of 60 years and above will account for a 34% higher share in the total population growing from one billion in 2019 to 1.4 billion in 2030.
For instance, as per the facts provided by the United Nations Fund for Population Activities (2021), it has been estimated that by 2050, the older population in the APAC region would reach to 1.3 billion, out of which 53% of the total population share would be accounted for by the females.
Some of the companies working in Menopause Market are ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc , Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen and Others.

To know more facts about Menopause Market Research Report, Click Here: Menopause Market Assessment

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Recent Developmental Activities in Menopause Market:

In September 2021, Theramex received the regualatory approval for Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. It is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and to be administered orally.
In April 2019, Amgen and UCB (Euronext Brussels: UCB) received the regulatory approval from the U.S. Food and Drug Administration (FDA) for EVENITY™ (romosozumab-aqqg) which is intended for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Know more in detail about the recent developmental activities: Menopause Treatment Landscape

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Menopause Companies:

ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc , Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen

To get free access to Detailed information on Menopause Market Analysis, Click here: Menopause Companies and Product

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Scope of the Menopause Market Report

Study Period: 2019 – 2027
Base Year: 2021
Forecast Period: 2022 – 2027
By Treatment Type (Hormonal Products, Non-Hormonal Products, And Dietary Supplements)
By Distribution Channel (Hospitals, Retail, And Online Pharmacies)
By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Delveinsight Analysis: Global menopause market was valued at USD 15.53 billion in 2021, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 23.44 billion by 2027.

Get free Access to the Menopause Sample Pages, Click here: Menopause Sample Report

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:

1. Menopause Market Report Introduction

2. Menopause Market Executive Summary

3. Regulatory Analysis

4. Menopause Market Key Factors Analysis

5. Menopause Market Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Menopause Market

7. Menopause Market Layout

8. Menopause Market Global Company Share Analysis & Key 3-5 Companies

9. Menopause Market Company and Product Profiles

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Latest Report:

About DelveInsight

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Acanthamoeba Keratitis Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Acanthamoeba Keratitis (AK) is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living ameba (a single-celled living organism) called Acanthamoeba. The organism causes AK when it infects the transparent outer covering of the eye called the cornea. The condition is very common in nature and can be found in water bodies (for example, lakes and oceans), soil, and air.

DelveInsight’s “Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Acanthamoeba Keratitis Market are:

As per a study conducted by Abelson et al. (2008), an estimated 5,000 cases of Acanthamoeba keratitis have occurred in the United States as of 2006, but since AK is so commonly misdiagnosed and the disease does not need to be reported to the Centers for Disease Control and Prevention, the actual number could be much higher. Approximately 88% of contact lens-related AK cases occur in soft contact lens wearers and 12% in rigid lens wearers.
According to the studies it has been estimated that the disease affect male and female equally.
According to Kozak et al. (2020), over 80% of Acanthamoeba keratitis appears in contact lens wearers. In one study, 75% of the patients were contact lens wearers; 40% wore daily soft lenses, 22% wore rigid gas permeable lenses, and 38% wore extended wear or other lenses.
According to Booton et al. (2009), the genotype of 15 Acanthamoeba sp. isolates from AK cases from this outbreak using sequence analysis of a region of the 18S rDNA were determined. The results indicated that the isolates were predominantly genotype T4 (87%), with the remaining isolates being genotype T3 (13%). Both genotypes had previously been observed in AK cases.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Scope of the Acanthamoeba Keratitis MarketReport

The report covers the descriptive overview of Acanthamoeba Keratitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Acanthamoeba Keratitis epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Acanthamoeba Keratitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Acanthamoeba Keratitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acanthamoeba Keratitis market.

Some of the Acanthamoeba Keratitis Companies are:

Polihexanide (PHMB)
And Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Acanthamoeba Keratitis Drugs:

SIFI
And Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Table of Contents:

1. Key Insights

2. Executive Summary of Acanthamoeba Keratitis

3. Competitive Intelligence Analysis for Acanthamoeba Keratitis

4. Acanthamoeba Keratitis: Market Overview at a Glance

5. Acanthamoeba Keratitis: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acanthamoeba Keratitis Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Acanthamoeba Keratitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acanthamoeba Keratitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Adult Growth Hormone Deficiency Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Adult Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Most cases of Adult Growth Hormone Deficiency (AGHD) result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult Growth Hormone Deficiency (AGHD) is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.

DelveInsight’s “Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Adult Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Adult Growth Hormone Deficiency Market are:

According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.
As per Jana Bujanova et al., estimates prevalence of AGHD in the UK is approximately 1 in 10 000 (a total of approximately 6380 patients). If Childhood-onset GH deficiency is added to this number then prevalence is 1 in 10 000 to 1 in 3500.
In a study, the author found that a greater proportion of Japanese adults had AO GHD than CO GHD, a finding similar to those of previous studies in Caucasian adults. In contrast, in a previous study of Japanese adults with GHD, only 45% of participants were reported to have AO GHD. That study, however, included a smaller number of participants than were included in the study and was conducted at a single institution. [Akira Shimatsu et al.,2011]
Adult Growth Hormone Deficiency is more common among males than females.

Scope of the Adult Growth Hormone Deficiency Market Report

The report covers the descriptive overview of Adult Growth Hormone Deficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Adult Growth Hormone Deficiency epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Adult Growth Hormone Deficiency is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Adult Growth Hormone Deficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adult Growth Hormone Deficiency market.

Some of Adult Growth Hormone Deficiency Companies are:

Novo Nordisk
Ascendis Pharma
And Many Others

Some of Adult Growth Hormone Deficiency Therapies are:

Sogroya (somapacitan-beco)
TransCon hGH
And Many Others

Table of Contents:

1. Key Insights

2. Executive Summary of Adult Growth Hormone Deficiency

3. Competitive Intelligence Analysis for Adult Growth Hormone Deficiency

4. Adult Growth Hormone Deficiency: Market Overview at a Glance

5. Adult Growth Hormone Deficiency: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Adult Growth Hormone Deficiency Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Adult Growth Hormone Deficiency: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Adult Growth Hormone Deficiency

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Chronic Idiopathic Urticaria Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Chronic idiopathic urticaria (CIU) is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or “wheals” on the skin. It is being associated with autoimmunity in almost half of the cases but the remaining cases still remains “idiopathic” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous, and independent of any external physical stimulus, which is conceptually helpful, and does not imply knowing or not-knowing the cause.

DelveInsight’s “Chronic Idiopathic Urticaria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Idiopathic Urticaria, historical and forecasted epidemiology as well as the Chronic Idiopathic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Chronic Idiopathic Urticaria Market are:

According to the study by Zuberbier T et al., 2010; lifetime prevalence for Chronic Urticaria was 1.8%. Women were more likely than men to have Chronic Urticaria (70.3% vs. 29.7%). The lifetime prevalence of urticaria: 7.8% (Germany). The estimates in the existing literature for the prevalence of CU range from 0.05% to 3%.
According to the study of Reham Ezz El-Dawla El-Sharkawy et al., 2018; the incidence of CU has been estimated at 1.4% per year in the USA with male to female ratio at 1: 3.7. Out of 108 patients, 58.3% were affected with CSU.
According to the study by Marcus Maurer et al., 2017; the estimated point prevalence of CIU is approximately 0.5% to 1% worldwide.
The first-line management of acute or chronic urticaria is focused on the use of H1 antihistamines, leukotriene antagonists and/or H2 receptor antagonists next. However, in Europe, treatment with sedating H1 antihistamines and H2 antihistamines are not recommended. Along with these there are few FDA approved therapy for treatment of CIU.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Scope of the Chronic Idiopathic Urticaria MarketReport

The report covers the descriptive overview of Chronic Idiopathic Urticaria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Chronic Idiopathic Urticaria epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Idiopathic Urticaria is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Chronic Idiopathic Urticaria market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Idiopathic Urticaria market.

Some of the Chronic Idiopathic Urticaria Companies are:

Novartis
Genentech
Kiniksa pharmaceuticals
UCB Inc.
Merck Sharp & Dohme Corp.
Sanofi-aventis
And Many Others.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Chronic Idiopathic Urticaria Drugs:

Xolair (omalizumab)
XYZAL (levocetirizine dihydrochloride)
CLARINEX (Desloratadine)
Allegra (fexofenadine hydrochloride)
Ligelizumab
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Table of Contents:

1. Key Insights

2. Executive Summary of Chronic Idiopathic Urticaria

3. Competitive Intelligence Analysis for Chronic Idiopathic Urticaria

4. Chronic Idiopathic Urticaria: Market Overview at a Glance

5. Chronic Idiopathic Urticaria: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Chronic Idiopathic Urticaria Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Chronic Idiopathic Urticaria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chronic Idiopathic Urticaria

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

DelveInsight’s Trending Reports 2022: Chondrosarcoma Market, Microsatellite Stable Colorectal Cancer Market, Rituximab Biosimilars Insight, Pain Management Devices Market, 22q11.2 Deletion Syndrome Market.

Chondrosarcoma Market

Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by syndrome.

Some of the facts:

According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer.
Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20.
Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance.
Chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. Malignant transformation occurs in 5% of osteochondromas, either multiple or solitary forms.

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

Some of the Chondrosarcoma Companies:

Agios Pharmaceuticals
Forma Therapeutics
Eli Lilly and Company
PharmaMar
And Many Others

Chondrosarcoma Drugs Covered:

AG-120
Olutasidenib
LY3410738
Trabectedin
And Many Others

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

Microsatellite Stable Colorectal Cancer Market

Microsatellite stable colorectal cancer bears fewer signals that alert the immune system to cancer. So checkpoint inhibitors, such as nivolumab, have been unsuccessful in treating MSS colorectal cancer (CRC). Clinical trials have been going on to develop the promising drug for MSS colorectal cancer.

Some facts of Microsatellite Stable Colorectal Cancer Market Report are:

Approximately 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2.
According to DelveInsight, Microsatellite Stable Colorectal Cancer Market is expected to grow at CAGR of XX% during the forecast period.
Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux are recent additions to the Metastatic Colorectal Cancer treatment market.
Talking about gender-predisposition, CRC is the third most commonly diagnosed cancer in males and the second in females. It is most frequently diagnosed in people of age group 65–74.

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Some of Microsatellite Stable Colorectal Cancer Companies in the market:

Gritstone Oncology
Merck Sharp & Dohme Corp.
Arrys Therapeutics
NeoImmuneTech
And Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Microsatellite Stable Colorectal Cancer Drugs:

GRANITE
MK7123-034
NT-I7
TPST-149
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Rituximab Biosimilars Insight

Rituximab is a type of antibody therapy, which can be used alone or with chemotherapy. They work in different ways to catch and attack the cells where cancer occurs. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used for treating certain types of cancer. It works by reducing or prohibiting the growth of cancer cells. This drug is also used for treatment of certain types of blood vessel disease, decrease the swelling of the blood vessels, and treat a specific skin condition.

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab Biosimilars Drugs covered in the report:-

IBI-301
RGB 03
RITUMAX
ABP 798
AcellBia/Usmal
Blitzima/Truxima
BX 2336
DRL_RI
GP2013
HLX01
iBio Rituximab
IBPB 001RX
MK-8808
Ritemvia/Blitzima
Riximyo
RTXM83
Ruxience
AP 052
Retuxira
TL-011
RituxiRel
Kikuzubam
LBRx
DRL-rituximab
MG1106
GB-241
Rilast
HS 006
BX 2336
GNR-006

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Scope of Rituximab Biosimilars report:

Major Players in Rituximab – 35+ key companies
Phases – 35+ products under different phases of clinical development
- Marketed stage products
- Late-stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration

Route of Administration
- Subcutaneous
- Intravenous
- Molecule Type
Molecule types
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type

Product Types

Mono
Combination
Mono/Combination

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Pain Management Devices Market

Pain management is a field of medical science that makes it easier for people with chronic pain who suffer. Acute pain has a rapid onset of action, while chronic pain lasts for a prolonged period of time, causing it to to be managed. Pain management device is a medical system used to treat various forms of pain, such as neuropathic pain, cancer pain, nociceptive pain, musculoskeletal pain, and others.

Some key facts of the Pain Management Devices Market:

Global Pain Management Devices Market is expected to grow at a CAGR of 7.89% during the forecast period from 2021 to 2026.
The demand for Pain Management Devices is primarily motivated by the rise in prevalence of chronic pain, high prevalence of musculoskeletal disorders, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and increasing cost of healthcare expenditure.
According to World Health Organization (2019), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

Some of the Pain Management Devices Companies are:

St. Jude Medical, Inc.
Boston Scientific Corporation
Medtronic plc
Smiths Medical
Abbott
Nevro Corp.
Stimwave LLC
And Many More

Pain Management Devices Market Drivers

Growing need for long-term pain relief in the geriatric consumer
Large & rising population base of patients
Adverse effects of pain medications
Widely demonstrated effectiveness of pain management devices

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

22q11.2 Deletion Syndrome Market

22q11.2 Deletion Syndrome is a condition that develops because of chromosome defects and is a complex, multi-organ disorder noted for its varying severity and penetrance among those affected. As per several studies, it is the most common chromosomal microdeletion reported in humans.

Some facts of 22q11.2 Deletion Syndrome Market are:

In 2020, the total prevalent cases of 22q11.2 deletion syndrome were 196,476 in the 7MM. The United States, in the same year, accounted for 83,326 cases, the highest prevalence of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020.
Among the EU-5 countries, the highest number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain in 2020.
22q11.2 deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. In the EU-5 countries, the total diagnosed prevalent cases of 22q11.2 deletion syndrome were 35,203 in 2020.
22q11.2 deletion syndrome is a multisystem disorder characterized by several physical, behavioral and psychiatric disorders. In the 7MM, of the focused age-group 6 to 12 and 13 to 17 years, the diagnosed prevalent cases of 22q11.2 deletion syndrome with Behavioral and Psychiatric Phenotypes were 36,702, in 2020.

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Some of 22q11.2 Deletion Syndrome Companies are:

Zynerba Pharmaceuticals
Enzyvant
Roivant Sciences
Sumitomo Dainippon Pharma
And Many Others

Some of 22q11.2 Deletion Syndrome Therapies are:

Zygel (ZYN002)
RVT-802
And Many Others

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

DelveInsight’s Trending Reports 2022: Ehlers-Danlos Syndrome Market, X Linked Hypophosphatemia Market, Thyroid Eye Disease Market, Primoridal Dwarfism Market, Sialidosis Market.

Ehlers-Danlos Syndrome Market

Ehlers-Danlos syndrome (EDS) is a disease that weakens the connective tissues of your body. These are things like tendons and ligaments that hold parts of your body together. EDS can make your joints loose and your skin thin and easily bruised. It also can weaken blood vessels and organs.

Some facts of Ehlers-Danlos Syndrome Market Report are:

The combined prevalence of all types of Ehlers-Danlos syndrome appears to be at least 1 in 5,000 individuals worldwide.
Vascular EDS is reported to have a prevalence of 1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1 in a million people.
The estimated prevalence for all EDS varies between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10% of cases.

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Some of Ehlers-Danlos Syndrome Companies are:

Aventis Pharmaceuticals
EVAMED
Acer Pharma
And Many Others

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Ehlers-Danlos Syndrome Therapies are:

Celiprolol
Irbesartan
And Many Others

X Linked Hypophosphatemia Market

X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets.

Some facts of X Linked Hypophosphatemia Market Report are:

According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000.
As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States
According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease.
The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000.

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

Some of X Linked Hypophosphatemia Companies are:

Ultragenyx
Validus Pharmaceuticals
Prospec-Tany Technogene Ltd
Merck KGaA
Zeria Pharmaceutical Co., Ltd
Smith & Nephew
Narang Medical Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
And Many Others

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

X Linked Hypophosphatemia Therapies are:

Burosumab
Crysvita
And Many Others

Thyroid Eye Disease Market

Thyroid eye disease (TED)—also known as Graves’ Orbitopathy or Ophthalmopathy—is an autoimmune condition. It occurs when the body’s immune system attacks the tissue surrounding the eye causing inflammation in the tissues around and behind the eye. It appears that the same antibody that can cause thyroid dysfunction may also have an “attraction”to tissuessurrounding the eyes causing the onset of Graves’ Ophthalmopathy. Moreover, the disease is categorized as mild, moderate, and severe.

Some of Thyroid eye disease Facts:

In a study by Zagaria et al. [2011], it was observed that approximately 25‐30% of patients with Graves’ disease have clinical evidence of Graves’ ophthalmopathy.
As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men).
The study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO) occurs mainly, but not exclusively, in patients with Graves’ disease. However, only about <50% of Graves’ patients have clinically apparent ophthalmopathy, where the approximate prevalence is 0.25%.
According to a review article titled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant in approximately 50% of patients with Graves’ disease, and severe forms affects less than 5% of patients.

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Some of Thyroid eye disease Companies:

Immunovant Sciences
Horizon Therapeutics
And Many Others

Thyroid eye disease Drugs Covered:

IMVT‐1401
Teprotumumab
And Many Others

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Primoridal Dwarfism Market

Primordial dwarfism is a rare and often dangerous group of genetic conditions that result in a small body size and other growth abnormalities. Signs of the condition first appear in the fetal stage and continue through childhood, adolescence, and adulthood.

Some facts of Primordial Dwarfism Market Report:

Primordial Dwarfism Market size is expected to change for 7MM during the forecast period of 2018-30.
Its prevalence report estimates 4 million babies to die in the ﬁrst 4 weeks of life (the neonatal period) with almost 99 % of neonatal deaths (Lawn et al. 2011; Cous-ens et al. 1995).
The modern prevalence of MOPDII is unknown, but between 150 and 200 cases are reported worldwide each year (Bober and Jackson, 2017).
All types of primordial dwarfism are caused by changes in genes. Different gene mutations cause the different conditions that make up primordial dwarfism.
Primordial dwarfism can be difficult to diagnose. This is because the small size and low body weight could be a sign of other things, such as poor nutrition or a metabolic disorder.

To get more detailed insight on Primordial Dwarfism Market Report @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market

Some of Primordial Dwarfism Companies are:

GeneScience Pharmaceuticals
Merck
Genentech, Inc.
Pfizer
Novo Nordisk
EMD Serono
And Many Others

Primordial Dwarfism Therapies are:

Jintrolong® low dose group
Recombinant human growth hormone (r-hGH)
Somatropin
And Many Others

To get more detailed insight about Primordial Dwarfism Therapies @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market

Sialidosis Market

Sialidosis is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this enzyme results in an abnormal accumulation of complex carbohydrates known as mucopolysaccharides, and of fatty substances known as mucolipids. Both of these substances accumulate in bodily tissues. There are four types of Sialidosis: Each type of Sialidosis is characterized by the age of onset and by the type of physical and mental manifestations of this disorder.

Some of Sialidosis facts:

As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry.
As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age.
According to NORD, Sialidosis affects males and females in equal number.
The prevalence is estimated to be less than 1/1,000,000.

View Report: https://www.delveinsight.com/report-store/sialidosis-market

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Age-related macular degeneration (AMD) Market is expected to showcase exceptional Growth by 2032 – Estimates DelveInsight | Key Companies- Roche, Opthea Limited, Apellis Pharma, IVERIC Bio, Novartis, & Others

Age-related macular degeneration (AMD) is a neurodegenerative disease of the aging retina, in which patients experience severe vision loss. AMD is one of the most prevalent ocular conditions in developed countries with more than 10 million US adults affected by AMD. Based on severity of the disease, It is of three stages: Early, Intermediate and Late-stage; Late stage AMD is of two types: Dry AMD and Neovascular AMD (nAMD).

AMD’s progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD’s exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD. This has led to identification of many new targets for controlling disease progression.

Click here to Request for Age Related Macular Degeneration Market Sample Page: https://www.delveinsight.com/report-store/age-related-macular-degeneration-market

DelveInsight’s “Age Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Age Related Macular Degeneration, historical and forecasted epidemiology as well as the Age Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Age-related macular degeneration (AMD) Market Report

According to Ayoub et al., Age-related macular degeneration (AMD) is the leading cause of blindness and visual disability in patients aged over 60 years in Europe and North America. It is the third leading cause of blindness, behind cataract and glaucoma, causing 8.7% of all legal blindness across the world.
Globally, around 20 million people are living with nAMD – the leading cause of cause of vision loss in people over the age of 60.
According to Braclay et al. (2021), based on types of AMD, dry AMD accounts for nearly 85-90% of the cases and Neovascular AMD (nAMD) accounts for only 10% of the cases, but nAMD is responsible for nearly 90% of the severe, central visual acuity loss associated with AMD.
According to Schwatz et al. (2021), dry AMD prevalence was reported as 0.44% globally, with similar or slightly higher values reported for wet AMD. Dry AMD prevalence varied across ethnic groups (1.11% European, 0.21% Asian, 0.16% Hispanic, and 0.14% African).
According to DelveInsight’s analysis, AMD is more prominent in females in comparison to males.
Among the age-specific cases of AMD, 61-70 years of age represents the biggest category, followed by 51-60 years of age.
The prevalence of AMD is poised to increase due to the increase in geriatric population in all 7MM.

Click here to Request for Age Related Macular Degeneration Market Sample Page: https://www.delveinsight.com/report-store/age-related-macular-degeneration-market

Scope of the Age-related macular degeneration (AMD) Market Report

The report covers the descriptive overview of Age Related Macular Degeneration, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Age Related Macular Degeneration epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Age Related Macular Degeneration is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Age Related Macular Degeneration market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Age Related Macular Degeneration market.

Click here to Request for Age Related Macular Degeneration Market Sample Page: https://www.delveinsight.com/report-store/age-related-macular-degeneration-market

Age-related macular degeneration (AMD) Companies are:

Roche
Opthea Limited
Apellis Pharma
IVERIC Bio
Novartis
Regeneron Pharmaceuticals
And Others

To get detailed insights into Age-related macular degeneration Pipeline therapies and companies working in the domain, Click here: https://www.delveinsight.com/sample-request/age-related-macular-degeneration-market

Age-related macular degeneration (AMD) Pipeline Drugs and Therapies:

Faricimab
OPT-302
APL-2
Beovu
Lucentis
Eylea
And Others

To get competitive insights into Age-related macular degeneration Pipeline, Click here: https://www.delveinsight.com/sample-request/age-related-macular-degeneration-market

Table of Content

1. Key Insights

2. Executive Summary

3. Age-related macular degeneration Competitive Intelligence Analysis

4. Age-related macular degeneration Market Overview at a Glance

5. Age-related macular degeneration Disease Background and Overview

6. Age-related macular degeneration Patient Journey

7. Age-related macular degeneration Epidemiology and Patient Population

8. Age-related macular degeneration Treatment Algorithm, Current Treatment, and Medical Practices

9. Age-related macular degeneration Unmet Needs

10. Key Endpoints of Age-related macular degeneration Treatment

11. Age-related macular degeneration Marketed Products

12. Age-related macular degeneration Emerging Therapies

13. Age-related macular degeneration Seven Major Market Analysis

14. Attribute Analysis

15. Age-related macular degeneration Market Outlook (7 major markets)

16. Age-related macular degeneration Access and Reimbursement Overview

17. KOL Views on the Age-related macular degeneration Market.

18. Age-related macular degeneration Market Drivers

19. Age-related macular degeneration Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Osteoarthritis Market is expected to showcase exceptional Growth by 2032 – Estimates DelveInsight | Key Companies- Novartis, Peptinov, 4P Pharma, Sorrento, Eupraxia, Biosplice, Ampio, Bone Therapeutics, & Others

Osteoarthritis, also known as the degenerative joint disease (DJD) is the most common form of arthritis. It occurs when the protective cartilage which cushions the ends of the bones wears over a period of time. The disease is likely to progress as people age. Inflammation and injury caused to the joint might lead to bony changes, deterioration of Tendons and ligaments and a breakdown of cartilage, resulting in pain, swelling, and deformity of the joint.

DelveInsight’s “Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Osteoarthritis, historical and forecasted epidemiology as well as the Osteoarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Some facts of Osteoarthritis Market Report:

According to the EULAR Study Group (2015), it was estimated that OA affects about 40 million people in Europe. It was relatively infrequent in people under the age of 40 years but increased definitely with age. Under the age of 45 women were less affected than males which reverse above the age of 45.
Osteoarthritis (OA) is the 4th leading cause of disability across the world and is thought to be the most prevalent of all musculoskeletal pathologies, affecting an estimated 10% of the world’s population over the age of 60.
According to Osteoarthritis Action Alliance, while there are estimated to be more than 100 types of arthritis, OA is the most common form of arthritis, affecting 32.5 million US adults. 43% of people with OA are 65 or older and 88% of people with OA are 45 or older. 62% of individuals with OA are women. Among people younger than 45, OA is more common among men; above age 45, OA is more common among women.
Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment can act as a market barrier.

Get More Detailed Insights into the Osteoarthritis Market Report: https://www.delveinsight.com/sample-request/osteoarthritis-market

Symptoms associated with osteoarthritis

Osteoarthritis symptoms tend to develop slowly and worsen gradually with time. The signs and symptoms of osteoarthritis include, pain as the affected joints might hurt as a result of movement, joint stiffness, tenderness, when the individual applies light pressure to or near it, loss of flexibility, grating sensation when the individual hears popping or crackling, bone spurs or extra bits of bone that feels like a hard lump and forms around the affected joint, swelling that might result due to soft tissue inflammation around the joint.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Osteoarthritis Diagnosis

Osteoarthritis is primarily a clinical diagnosis. However, plain radiography can be helpful in confirming the diagnosis and ruling out other pathology.34 MRI and computed tomography are rarely needed. There are certain plain radiographic findings characteristic of Osteoarthritis. Osteoarthritis often demonstrates joint space narrowing, osteophyte formation, subchondral sclerosis, and cysts.

Key Benefits of Osteoarthritis Market Report

The report provides an in-depth analysis of Osteoarthritis Market Size and Share till 2032 in the 7MM.
The report will help in developing business strategies by understanding the Osteoarthritis Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.
It covers Osteoarthritis’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
The report provides a detailed assessment of the Osteoarthritis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Osteoarthritis Pipeline therapies and Companies:

DK 004: Jiangsu Carephar Pharmaceutical
4P-004: 4P Pharma
LNA043: Novartis
LRX712: Novartis
X 0002: Techfields Pharma
DMI 9523: Ampio Pharmaceuticals
PPV-06: Peptinov
And Others.

Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/osteoarthritis-market

The Osteoarthritis therapeutics market has a promising outlook with the emerging therapies, consisting of several Phase III and Phase II assets.

Osteoarthritis Market Drivers

Growing geriatric population and hence the rising prevalence of osteoarthritis
Favorable government policies to support the development of new therapies for the Osteoarthritis, and Others

Table of Content

1. Key Insights

2. Executive Summary

3. Osteoarthritis Competitive Intelligence Analysis

4. Osteoarthritis Market Overview at a Glance

5. Osteoarthritis Disease Background and Overview

6. Osteoarthritis Patient Journey

7. Osteoarthritis Epidemiology and Patient Population

8. Osteoarthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Osteoarthritis Unmet Needs

10. Key Endpoints of Osteoarthritis Treatment

11. Osteoarthritis Marketed Products

12. Osteoarthritis Emerging Therapies

13. Osteoarthritis Seven Major Market Analysis

14. Attribute Analysis

15. Osteoarthritis Market Outlook (7 major markets)

16. Osteoarthritis Access and Reimbursement Overview

17. KOL Views on the Osteoarthritis Market.

18. Osteoarthritis Market Drivers

19. Osteoarthritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

About DelveInsight